Side effect(s) of Ribociclib

Last Updated on Jun 03, 2023

Review the side-effects of Ribociclib as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the instances these side-effects are mild and easily tolerable, however sometimes they can be more severe and can be detrimental.

If the side effects are not tolerable adjusting the dosage or switching to a different medication can help to manage or overcome side effects. If you have any doubts or questions, we recommend seeking advice from your doctor or pharmacist.

  Common: Headache, weakness, low white blood cell counts, gastrointestinal disturbances, QT interval prolongation in the heart

  Gastrointestinal: Nausea, vomiting, diarrhea, stomach pain, constipation, stomatitis, loss of appetite, increase in liver enzymes

  Skin: Alopecia (loss of hair), itching, rashes

  Central nervous system: Headache, difficulty in falling asleep, syncope (temporary loss of consciousness), increase in body temperature

  Respiratory: Difficulty in breathing, sorethroat

  Blood: Decreased counts of hemoglobin, leukocytes, platelets, neutrophils and/or lymphocytes

  Others: Back pain, urinary tract infection, peripheral edema

Other Precautions :

Avoid excess dose.
Do not use either a broken or a damaged tablet.

Drug Name : Ribociclib

Ribociclib generic Ribociclib belongs to a class of medications called kinase inhibitors; it inhibits the cyclin-dependent kinase (CDK) 4 and 6. It is used for treating hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in post-menopausal women. It is used along with another anticancer drug belonging to the aromatase inhibitor group such as letrozole. Ribociclib acts by blocking the action of an abnormal protein which eventually interferes with the cell multiplication, and thereby results in either slowing down or stopping the spread of cancer cells.

Last Updated on Jun 03, 2023